Nicholas Piramal has tied up with the Council of Scientific Industrial Research (CSIR) to file an exclusive marketing right (EMR) for its anti-malaria drug Aablaquine (bulaquine).
Nicholas Piramal launched Bulaquin with chloroquine a combination therapy with brand name Aablaquine to control Plasmodium vivax malaria more effectively without side effects.
Bulaquin, primarily a primaquine derivative, is the international non-proprietary name (INN) of a compound developed under house number “Compound 80/53” by The Central Drug Research Institute. The molecule has been licenced to Nicholas Piramal India for marketing.
Early this year, Nicholas Piramal had also filed application for EMR for its other anti-malarial drug Movoquin. Other companies that have applied for EMRs in the past, include: Wockhardt for antibiotic Benzoquinolizines, Ranbaxy for a process of antibiotic Cipro, Schering Plough for bio-tech cancer drug Interferon alpha and Bayer for antibiotic Gatefloxacin.
Some EMR applications rejected by the authorities include Roche’s HIV/AIDS drug Saquinavir, GlaxoSmithKline's anti-diabetic drug Rosiglitazone and Ranbaxy for a new drug delivery system.